Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus anlotinib with dynamic TIL modeling in previously treated progressive small cell lung cancer
ChiCTR2000034466Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and anlotinib in small cell lung cancer (SCLC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Dynamic model of TIL changes before and after first-line chemotherapy in SCLC. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
sintilimabanlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2000034466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034466.